​

Solid Biosciences (SLDB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SLDB Stock Forecast

Solid Biosciences (SLDB) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $20.00, with a high of $26.00 and a low of $16.00. This represents a 101.41% increase from the last price of $9.93.

- $6 $12 $18 $24 $30 High: $26 Avg: $20 Low: $16 Last Closed Price: $9.93

SLDB Stock Rating

Solid Biosciences stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (78.26%), 5 Hold (21.74%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 23 0 5 18 Strong Sell Sell Hold Buy Strong Buy

SLDB Price Target Upside V Benchmarks

TypeNameUpside
StockSolid Biosciences101.41%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts226
Avg Price Target$23.00$23.00$17.50
Last Closing Price$9.93$9.93$9.93
Upside/Downside131.62%131.62%76.23%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2649---13
Aug, 2648---12
Jul, 26410---14
Jun, 26410---14
May, 2649---13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 27, 2026Cantor Fitzgerald$26.00$9.72167.49%161.83%
Aug 21, 2026Danielle BrillTruist Financial$20.00$9.10119.78%101.41%
May 13, 2026Wedbush$16.00$7.74106.72%61.13%
May 13, 2026Biren AminPiper Sandler$18.00$7.72133.16%81.27%
Dec 04, 2025Gil BlumNeedham$16.00$5.19208.29%61.13%
Nov 04, 2025Barclays$9.00$5.2073.08%-9.37%
Jul 21, 2025Charles DuncanCantor Fitzgerald$16.00$6.76136.69%61.13%
Jun 24, 2024Joseph SchwartzLeerink Partners$12.00$6.6281.27%20.85%
May 31, 2024Biren AminPiper Sandler$20.00$7.64161.78%101.41%
May 16, 2024Gena WangBarclays$18.00$9.6985.76%81.27%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 27, 2026Cantor FitzgeraldOverweightOverweighthold
Jun 03, 2026H.C. WainwrightBuyBuyhold
May 13, 2026Piper SandlerOverweightOverweighthold
Dec 17, 2025CitigroupMarket OutperformMarket Outperformhold
Dec 04, 2025NeedhamBuyinitialise
Jul 21, 2025Cantor FitzgeraldOverweightOverweighthold
Jun 26, 2025CitigroupBuyinitialise
Jun 17, 2025H.C. WainwrightBuyBuyhold
Aug 14, 2024H.C. WainwrightBuyBuyhold
Jun 24, 2024Leerink PartnersOutperformupgrade

Financial Forecast

EPS Forecast

$-11 $-9 $-7 $-5 $-3 $-1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-10.14$-10.10$-4.83$-3.06$-1.99---
Avg Forecast$-10.77$-6.83$-4.76$-2.89$-2.90$-2.79$-3.03$-2.00
High Forecast$-10.77$-6.83$-3.91$-2.71$-2.09$-1.83$-2.26$-2.00
Low Forecast$-10.77$-6.83$-5.16$-3.03$-3.60$-4.46$-5.18$-2.00
Surprise %-5.85%47.88%1.47%5.88%-31.38%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$13.62M$8.09M------
Avg Forecast$12.10M$8.10M$1.10M$1.21M$1.49M$2.34M$22.70M$116.10M
High Forecast$12.10M$8.10M$1.10M$1.21M$1.49M$2.34M$22.70M$116.10M
Low Forecast$12.10M$8.10M$1.10M$1.21M$1.49M$2.34M$22.70M$116.10M
Surprise %12.57%-0.05%------

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-72.19M$-85.98M$-96.02M$-124.70M$-174.32M---
Avg Forecast$-214.15M$-135.78M$-96.02M$-57.04M$-56.62M$-62.58M$-73.92M$-39.67M
High Forecast$-214.15M$-135.78M$-77.65M$-53.90M$-41.64M$-36.45M$-44.90M$-39.67M
Low Forecast$-214.15M$-135.78M$-102.61M$-60.18M$-71.59M$-88.72M$-102.95M$-39.67M
Surprise %-66.29%-36.68%-118.61%207.90%---

SLDB Forecast FAQ

Is Solid Biosciences stock a buy?

Solid Biosciences stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Solid Biosciences is a favorable investment for most analysts.

What is Solid Biosciences's price target?

Solid Biosciences's price target, set by 23 Wall Street analysts, averages $20 over the next 12 months. The price target range spans from $16 at the low end to $26 at the high end, suggesting a potential 101.41% change from the previous closing price of $9.93.

How does Solid Biosciences stock forecast compare to its benchmarks?

Solid Biosciences's stock forecast shows a 101.41% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Solid Biosciences over the past three months?

  • September 2026: 30.77% Strong Buy, 69.23% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Solid Biosciences’s EPS forecast?

Solid Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.79, marking a 40.20% increase from the reported $-1.99 in 2025. Estimates for the following years are $-3.03 in 2027, and $-2 in 2028.

What is Solid Biosciences’s revenue forecast?

Solid Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $2.34M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $22.7M, and $116.1M for 2028.

What is Solid Biosciences’s net income forecast?

Solid Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-62.585M, representing a -64.10% decrease from the reported $-174M in 2025. Projections indicate $-73.922M in 2027, and $-39.669M in 2028.